Codexis Announces New Employment Inducement Grants
Codexis (NASDAQ: CDXS) has announced the approval of equity grants for two new employees, as authorized by the company's Compensation Committee. The inducement awards, issued under the 2024 Inducement Plan, include:
- Stock options to purchase 10,000 shares, with an exercise price matching Codexis' Nasdaq closing price on the grant date
- 5,000 restricted stock units (RSUs)
The stock options vest over four years, with 25% vesting after the first year and the remainder vesting monthly thereafter. The RSUs will vest in equal annual installments over three years. Both grants require continued employment with Codexis through applicable vesting dates.
Codexis (NASDAQ: CDXS) ha annunciato l'approvazione di concessioni di azioni per due nuovi dipendenti, come autorizzato dal Comitato per la Compensazione dell'azienda. I premi di incentivazione, emessi nell'ambito del Piano di Incentivazione 2024, includono:
- Opzioni su azioni per l'acquisto di 10.000 azioni, con un prezzo di esercizio pari al prezzo di chiusura di Codexis su Nasdaq alla data di concessione
- 5.000 unità di azioni vincolate (RSU)
Le opzioni su azioni maturano in quattro anni, con il 25% che matura dopo il primo anno e il resto che matura mensilmente successivamente. Le RSU matureranno in rate annuali uguali per tre anni. Entrambe le concessioni richiedono un'occupazione continuativa con Codexis fino alle date di maturazione applicabili.
Codexis (NASDAQ: CDXS) ha anunciado la aprobación de concesiones de acciones para dos nuevos empleados, como lo autorizó el Comité de Compensación de la empresa. Los premios de inducción, emitidos bajo el Plan de Inducción 2024, incluyen:
- Opciones sobre acciones para comprar 10,000 acciones, con un precio de ejercicio igual al precio de cierre de Codexis en Nasdaq en la fecha de concesión
- 5,000 unidades de acciones restringidas (RSUs)
Las opciones sobre acciones se consolidan durante cuatro años, con el 25% consolidándose después del primer año y el resto consolidándose mensualmente a partir de entonces. Las RSUs se consolidarán en cuotas anuales iguales durante tres años. Ambas concesiones requieren empleo continuo con Codexis hasta las fechas de consolidación aplicables.
Codexis (NASDAQ: CDXS)는 회사의 보상 위원회에 의해 승인된 두 명의 새로운 직원에 대한 주식 보상을 발표했습니다. 2024 유인 계획에 따라 발행된 유인 상은 다음과 같습니다:
- 부여일의 Codexis 나스닥 종가와 일치하는 행사 가격으로 10,000주를 구매할 수 있는 주식 옵션
- 5,000 제한 주식 단위(RSU)
주식 옵션은 4년에 걸쳐 베스팅되며, 첫 해에 25%가 베스팅되고 나머지는 이후 매월 베스팅됩니다. RSU는 3년에 걸쳐 균등한 연간 할부로 베스팅됩니다. 두 가지 보상 모두 해당 베스팅 날짜까지 Codexis에서 지속적인 고용을 요구합니다.
Codexis (NASDAQ: CDXS) a annoncé l'approbation de la concession d'actions pour deux nouveaux employés, comme autorisé par le Comité de Rémunération de l'entreprise. Les récompenses d'incitation, émises dans le cadre du Plan d'Incitation 2024, comprennent :
- Des options d'achat d'actions pour l'acquisition de 10 000 actions, avec un prix d'exercice correspondant au prix de clôture de Codexis sur le Nasdaq à la date de concession
- 5 000 unités d'actions restreintes (RSU)
Les options d'achat d'actions se libèrent sur quatre ans, avec 25 % se libérant après la première année et le reste se libérant mensuellement par la suite. Les RSU se libéreront en versements annuels égaux sur trois ans. Les deux concessions nécessitent un emploi continu chez Codexis jusqu'aux dates de libération applicables.
Codexis (NASDAQ: CDXS) hat die Genehmigung von Aktienzuwendungen für zwei neue Mitarbeiter angekündigt, wie vom Vergütungsausschuss des Unternehmens genehmigt. Die Anreizvergaben, die im Rahmen des 2024 Anreizplans ausgegeben werden, umfassen:
- Aktienoptionen zum Kauf von 10.000 Aktien, mit einem Ausübungspreis, der dem Schlusskurs von Codexis an der Nasdaq am Datum der Gewährung entspricht
- 5.000 eingeschränkte Aktieneinheiten (RSUs)
Die Aktienoptionen werden über vier Jahre fällig, wobei 25 % nach dem ersten Jahr fällig werden und der Rest monatlich danach fällig wird. Die RSUs werden in gleichen jährlichen Raten über drei Jahre fällig. Beide Zuwendungen erfordern eine fortgesetzte Beschäftigung bei Codexis bis zu den entsprechenden Fälligkeitsdaten.
- None.
- None.
REDWOOD CITY, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to two new employees as approved by the Compensation Committee of Codexis’ Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 10,000 shares of Codexis common stock and (ii) 5,000 restricted stock units (RSUs) as inducement awards under the Company’s 2024 Inducement Plan.
The stock options have an exercise price equal to the closing price per share of Codexis’ common stock as reported by Nasdaq on the grant date, and vest over four years, with 25 percent of the shares vesting on the first anniversary of the vesting commencement date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to each employee’s continued service with Codexis through the applicable vesting dates. The RSUs will vest in equal annual installments on each anniversary of the grant date, until the third anniversary of such date, subject to each employee’s continued service with Codexis through the applicable vesting dates.
Codexis is providing this information in accordance with Nasdaq Listing Rule 5635(c)4.
About Codexis
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule and nucleic acid therapeutics manufacturing. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit www.codexis.com.
For More Information
Carrie McKim
(336) 608-9706
ir@codexis.com
FAQ
What equity grants did Codexis (CDXS) approve for new employees in March 2025?
How do the vesting terms work for Codexis' (CDXS) new employee stock options?
What is the vesting schedule for the RSUs granted by Codexis (CDXS)?
What is the exercise price for the stock options granted by Codexis (CDXS)?
